Sandoz Humira Biosimilar Set For 2023 After AbbVie Deal
Novartis AG unit Sandoz will get to launch its biosimilar of AbbVie Inc.'s immunosuppressant Humira in the U.S. on Sept. 30, 2023, and in Europe on Tuesday as part of a...To view the full article, register now.
Already a subscriber? Click here to view full article